Eleftha 150 mg Injection
  1. Home
  2. Pharma Products
  3. Intas Pharmaceuticals Ltd
  4. Eleftha 150 mg Injection

Eleftha 150 mg Injection

Eleftha 150 mg Injection contains trastuzumab 150 mg, a targeted monoclonal antibody used in cancer treatment. It is mainly used for HER2-positive breast cancer and certain HER2-positive stomach cancers. The medicine is given by intravenous infusion under the supervision of a qualified healthcare professional.

BUY NOW

Category

Trastuzumab works by binding to the HER2 protein on cancer cells and blocking signals that support their growth and division. It can be used alone or with chemotherapy and other medicines depending on the patient’s treatment plan. Regular monitoring is important because treatment may cause infusion-related reactions and can affect heart function in some patients. The dosage and treatment schedule are determined by the oncologist according to the cancer type, HER2 status, and treatment response.

Technical Specification

Specification Details
Active Ingredient Trastuzumab
Strength 150 mg
Dosage Form Powder for Injection
Route of Administration Intravenous Infusion
Pack Size 1 Vial
Manufacturer/Marketer Intas Pharmaceuticals Ltd

Product Also Known As

Eleftha 150mg Injection, Eleftha 150 mg Injection, Eleftha 150mg Vial, Trastuzumab 150mg Injection, Trastuzumab 150 mg Injection, Trastuzumab 150mg Vial, HER2 Targeted Therapy Injection